Abstract 215P
Background
Introduction: About 2-3% of all cancers are renal cell carcinoma (RCC). Nephrectomy is the main treatment. The decision among radical and partial nephrectomy often relies on the tumor size diagnosed by CT scan. It is thus justified to investigate the variation between the radiologic and pathologic size of the tumor and its implications on the management of renal cell carcinoma. Aim: To assess the variation between the radiologic tumor size (RTS) of localized renal cell cancer as measured by Computed tomography (CT) preoperatively and the pathologic tumor size (PTS) as determined from surgical specimen postoperatively.
Methods
The records of 240 patients who underwent nephrectomy due to RCC were taken from the Urology Department of Trivandrum Medical College, Kerala, India. The difference of means for the tumor size on Computed Tomography (CT) scan/ the radiologic tumor size (RTS) and pathologic tumor size (PTS) was calculated using paired T test; the difference was also categorised in terms of sex, type of RCC, type of nephrectomy and T staging. A p value of < 0.05 was considered statistically significant.
Results
The mean age of cases included was 54.82 years (22-78 years) (SD 10.991). The mean RTS was larger than PTS (5.22 ± 2.15 vs. 4.98 ± 2.04 cm, p = <0.001) with a discrepancy of 0.24 cm. The difference among means was found significant for both males and females; significant among clear cell RCC and non - clear cell RCC; and significant for radical neohrectomy but not for partial nephrectomy. Overall 41 of the 240 tumors were down-staged while another 5 up-staged.
Table: 215P Characteristics of the 240 patients with localized renal cell carcinoma
Number of patients | 240 | |
Average age (years) | 54.82 (SD 10.991) | |
Gender- | ||
Male | 159 (66.2%) | |
Female | 81 (33.8%) | |
Histopathologic type- | ||
Clear Cell Carcinoma | 198 (82.5%) | |
Total-Non Clear Cell Carcinoma | 42 (17.5%) | |
Papillary | 22 (9.2%) | |
Chromophobe | 7 (2.9%) | |
PNET | 3 (1.2%) | |
Sarcomatoid | 5 (2.1%) | |
Unclassified | 5 (2.1%) | |
Average tumor size- | ||
RTS | 5.22 (SD 2.15) | |
PTS | 4.98 (SD 2.04) | |
Average difference between RTS and PTS- | 0.24 (SD 0.37) | |
Fuhrman grade | ||
I | 10 (4.2%) | |
II | 177 (73.8%) | |
III | 45 (18.8%) | |
IV | 8 (3.3%) | |
T stage- | Radiologic | Pathologic |
T1a | 100 (41.7%) | 121 (50.4%) |
T1b | 102 (42.5%) | 95 (39.6%) |
T2a | 30 (12.5%) | 17 (7.1%) |
T2b | 8 (3.3%) | 7 (2.9%) |
Stage change- | ||
Down-staged | 41 (17.1%) | |
Up-staged | 5 (2.1%) | |
Total | 46 (19.2%) |
Conclusions
There can be a discrepancy between radiologic size and pathologic tumor size in renal cell cancer which bears repercussions for its management. Message: Mangement of renal cell carcinoma should be carefully selected based on the tumor size diagnosed by CT scan.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
329P - High-level expression of HDAC10 is associated with PD-L1 expression and poor prognosis in patients with non-small cell lung cancer receiving pulmonectomy
Presenter: Xiaomei Liu
Session: Poster display session
Resources:
Abstract
331P - A retrospective analysis of immune checkpoint therapy in patients with non-small cell lung cancer: Focus on thyroid disorder
Presenter: Sawana Ono
Session: Poster display session
Resources:
Abstract
332P - Analyse the association between adverse events (AEs) and survival in patients treated with immune checkpoint inhibitors (ICIs)
Presenter: Chi-yuan Cheng
Session: Poster display session
Resources:
Abstract
333P - Study of searching on efficacy of immune checkpoint inhibitor for the non-small cell lung cancer using FDG-PET/CT and thallium SPECT
Presenter: KAYOKO Kibata
Session: Poster display session
Resources:
Abstract
334P - Incidence and characteristic of adrenal insufficiency due to immune checkpoint inhibitors therapy
Presenter: Daisuke Etoh
Session: Poster display session
Resources:
Abstract
335P - PD-L1 profile of nasopharyngeal cancer patients in Indonesia
Presenter: Handoko Handoko
Session: Poster display session
Resources:
Abstract
336P - Pembrolizumab plus chemotherapy versus pembrolizumab monotherapy for PD-L1-positive advanced non-small cell lung cancer in the real world
Presenter: Jun Sugisaka
Session: Poster display session
Resources:
Abstract
337P - Neutrophil-to-Lymphocyte ratio as a predictive factor for hyperprogressive disease in NSCLC patients treated with immune checkpoint inhibitor
Presenter: Ryo Takahashi
Session: Poster display session
Resources:
Abstract
338P - A new insight into tumour immune-evasion: Crosstalk between cancer stem cells and T regulatory cells
Presenter: Abhishek Dutta
Session: Poster display session
Resources:
Abstract
339TiP - PACIFIC-5: Phase III study of durvalumab after either concurrent or sequential chemoradiotherapy (CRT) in patients with stage III NSCLC
Presenter: Yi-Long Wu
Session: Poster display session
Resources:
Abstract